QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Hims & Hers Health (HIMS) Stock Forecast & Price Target

$9.52
+0.07 (+0.74%)
(As of 02/23/2024 ET)

Hims & Hers Health Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$12.27
28.98% Upside
High Forecast$18.00
Average Forecast$12.27
Low Forecast$9.00
TypeCurrent Forecast
2/23/23 to 2/23/24
1 Month Ago
1/24/23 to 1/24/24
3 Months Ago
11/25/22 to 11/25/23
1 Year Ago
2/23/22 to 2/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$12.27$12.17$12.36$8.75
Predicted Upside28.98% Upside33.21% Upside34.20% Upside45.90% Upside
Get Hims & Hers Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.


HIMS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HIMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Hims & Hers Health Stock vs. The Competition

TypeHims & Hers HealthMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside29.87% Upside1,076.55% Upside7.77% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/5/2024Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$14.00 ➝ $15.00+81.38%
12/7/2023Imperial Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageInline$9.00+1.12%
8/9/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$12.00 ➝ $10.00+34.95%
8/8/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$11.00 ➝ $10.00+26.26%
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$14.00+77.22%
7/28/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$11.00+30.95%
5/9/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$13.50 ➝ $15.00+38.89%
4/27/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$15.00 ➝ $18.00+60.86%
4/11/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$10.00+2.04%
3/1/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$7.00 ➝ $9.00-23.01%
2/28/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$9.00 ➝ $14.00+45.08%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:37 PM ET.












HIMS Price Target - Frequently Asked Questions

What is Hims & Hers Health's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Hims & Hers Health stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for HIMS. The average twelve-month price prediction for Hims & Hers Health is $12.27 with a high price target of $18.00 and a low price target of $9.00. Learn more on HIMS's analyst rating history.

Do Wall Street analysts like Hims & Hers Health more than its competitors?

Analysts like Hims & Hers Health less than other Medical companies. The consensus rating score for Hims & Hers Health is 2.67 while the average consensus rating score for medical companies is 2.68. Learn more on how HIMS compares to other companies.

Does Hims & Hers Health's stock price have much upside?

According to analysts, Hims & Hers Health's stock has a predicted upside of 33.35% based on their 12-month stock forecasts.

What analysts cover Hims & Hers Health?

Hims & Hers Health has been rated by Imperial Capital, and Tigress Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:HIMS) was last updated on 2/23/2024 by MarketBeat.com Staff